In a recent filing with the SEC, Jeremy Green 's Redmile Group , which has been consistently accumulating shares of Array Biopharma Inc for the past seven quarters, revealed that it has diluted some of its stake in the company. Although Redmile Group currently owns almost 15.4 million shares, or 10.83% of all outstanding shares of Array Biopharma, which represents a 13% increase from the more than 13.6 million shares of the company that it owned at the end of June, it is nonetheless significantly lower than the 17.2 million shares it revealed owning in a regulatory filing around a fortnight ago.